UPDATE 2: US: Pfizer seeks "maximum value" from baby food unit
US pharmaceutical group Pfizer has insisted it will get maximum value for its shareholders out of any move to separate its infant nutrition business.
"The nutrition business is a highly-valued asset, and our decision about strategic options will be driven by value creation for the business and delivering the best after-tax value for our shareholders," a spokesperson for the company told just-food today (18 April).
Reports have suggested that Pfizer is nearing a deal to sell its infant nutrition unit for US$9-10bn.
Pfizer declined to comment directly on the reports. However, the spokesperson added "no decisions have been made" and insisted the group is in the "ongoing" process of "exploring strategic alternatives" for the unit.
When contacted by just-food Nestle declined to comment, while Danone was not immediately available for comment.
Last week brought further evidence of the difficulties facing food manufacturers as they look to grow their businesses in the developed markets of the US and Europe....
- Comment: Paying the price for eating healthily
- Why Nestle is relaxed about the China "drag"
- Focus: Will Danone return to growth in dairy?
- M&A Watch: Emmi shareholders should consider sale
- Focus: Why French retail deals could hit suppliers
- Nestle organic sales fall on Asia, Europe
- Danone "eyes acquisition of Mead Johnson"
- Heinz jobs in Australasia to go in restructuring
- Symington's acquires Tanfield Foods
- Heinz silent over Polish factory expansion talk